![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 01, 2016 1:17:25 PM
We all know ONCS has been working with the GP96 and OX40L DNA plasmids in the preclinical setting. I think these agents administered together with IL-12 would greatly improve responses. But I also wonder if EP checkpoint inhibitors would add the "icing on the cake" if they too were to be administered in solid tumors in combination with these other agents.
As for metastatic lesions, I think the EP combination of IL-12/GP96/OX40L/anti-pd-1 (or anti-pdl1) would theoretically drive a significant abscopal effect by increasing the number of tumor infiltrating lymphocytes in non-treated lesions. In such cases where the TIL are "braked" by checkpoints in these distant lesions - which by the way is very likely due to the potential for exhausted phenotype in immune cells - at that point you would administer systemic checkpoint inhibitors. Again, this systemic application would be limited to advanced metastatic lesion situations - the TIL would be there, but they would be stopped by the checkpoints.
I additionally think there could be another use for an IL-12/GP96/OX40L/anti-pd-1 (or anti-pdl1) EP combination in the adjuvant setting, i.e. prior to surgical removal. This would theoretically contribute to an adaptive immune response that prevents recurrences or progression.
My primary question is whether or not the immune response would play out this way when you electroporate checkpoint inhibitor DNA in the tumor cells and in these settings.
Any thoughts?
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM